Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort

Data Supplement

• Supplemental Data -

  Supplementary File 1. Full Raw and Analyzed Metabolomics Dataset.
  

• Supplemental Data -

  Figure S1. Overview of annotation workflow.
  

  Figure S2. Metabolic differences between diet/lifestyle (T2D-DL) and control groups.
  

  Figure S3. Metabolic differences between metformin (T2D-M) and control groups.
  

  Table S1. Significantly altered metabolites between T2D-DL (Diet and Lifestyle) and nondiabetic.
  

  Table S2. Significantly altered metabolites between T2D-M (metformin-treated group) and nondiabetic.